Skip to main content
 

Biosimilars Forum Applauds Senate Passage of the FDA Reauthorization Act

Washington, D.C. (August 3, 2017) – Today, the Biosimilars Forum issued the following statement on passage of the Food and Drug Administration Reauthorization Act (FDARA):

The Biosimilars Forum applauds Senate passage of the FDA Reauthorization Act. This legislation provides the agency with the resources it needs to effectively and efficiently review applications and ultimately enable biosimilars to reach the patients waiting for them. The bill also improves management and accountability at FDA by putting in place programmatic and fiscal evaluation mechanisms.

“We urge President Trump to sign this into law immediately as passage of this reauthorization is an important step toward increasing access to lifesaving medicines for so many in need.


About the Biosimilars Forum

The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.

To learn more about biosimilars, the Forum, and how to get involved, visit BiosimilarsForum.org, @USBiosimilars, or go to facebook/USBiosimilars to follow related conversations and join the dialogue.

Contact:
Aimee Steel Lubin
202.828.1895
aimee.lubin@hklaw.com
biosimilars@fkhealth.com

Date

Thursday, August 3, 2017